Scar News and Research

RSS

London hospital implants world’s first leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced the first post-approval implant of the Nanostim™ leadless pacemaker in the U.K. The world's first retrievable leadless pacemaker was implanted at St. Bartholomew's Hospital in London by Professor Richard Schilling.

27 Jan 2014

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.

24 Jan 2014

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

scar Fern-ndez-Capetillo's research group has developed compounds that only a few weeks ago were licensed by the Spanish National Cancer Research Centre (CNIO) to a pharmaceutical company for the creation of new anti-tumour drugs.

16 Jan 2014

Cosmetic results after "lumpectomy" differ for African-American versus Caucasian women

As perceived by both patients and doctors, the cosmetic results after "lumpectomy" for breast cancer differ for African-American versus Caucasian women, suggests a pilot study in the Plastic and Reconstructive Surgery-Global Open-, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).

9 Jan 2014

Transplanting self-donated Schwann cells aids hind limb functional recovery

A study carried out at the University of Miami Miller School of Medicine for "The Miami Project to Cure Paralysis" has found that transplanting self-donated Schwann cells (SCs, the principal ensheathing cells of the nervous system) that are elongated so as to bridge scar tissue in the injured spinal cord, aids hind limb functional recovery in rats modeled with spinal cord injury.

24 Dec 2013

Research: Beatboxing may be gentler on injury-prone vocal cords

You might think that beatboxing, with its harsh, high-energy percussive sounds, would be harder on the voice than the sweet song of a soprano. But according to new research by voice expert Dr. H. Steven Sims of the University of Illinois Hospital & Health Sciences System, beatboxing may actually be gentler on the injury-prone vocal cords. His findings were published Dec. 23 online in the Journal of Voice.

24 Dec 2013

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

UC San Diego Sulpizio Cardiovascular Center (SCVC) has been featured in the latest Becker's Hospital Review list of "100 Hospitals with Great Heart Programs."

20 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Professor wins $1M to create medical devices that lead to greater control of prosthetics in soldiers

Dr. Walter Voit, assistant professor of materials science and engineering and mechanical engineering at The University of Texas at Dallas, has been awarded $1 million to create medical devices that will lead to greater control of prosthetics in wounded soldiers.

17 Dec 2013

Bipolar disorder patients hold contradictory self-associations

Symptomatic bipolar disorder patients have a marked discrepancy between their automatic and “thought-out” views of themselves, research suggests.

13 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Exposure for even fractions of a second to high-powered blue handheld laser devices can cause serious eye injuries, according to a study recently released online in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers have concluded that the wide availability of these devices, which are often marketed as toys, could lead to an epidemic of ocular injuries, and greater public awareness and government intervention should be encouraged.

6 Dec 2013

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Study sheds new light on neuropsychiatric disorders

Trauma can scar people so indelibly that their children are affected. History provides examples of generations traumatized by war and starvation, whose children experience altered physiology.

4 Dec 2013

Current laser therapy approaches provide effective treatment for excessive scars

Current laser therapy approaches are effective for treating excessive scars resulting from abnormal wound healing, concludes a special topic paper in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

27 Nov 2013

Study: Use of bone marrow mononuclear stem cells does not improve heart function

New data reported by the Cardiovascular Cell Therapy Research Network (CCTRN) at the 2013 Scientific Sessions of the American Heart Association in Dallas showed that the use of bone marrow mononuclear stem cells (BMCs) did not improve heart function significantly more at one year than at six months.

19 Nov 2013

High-power blue laser gadgets can cause serious eye damage

A type of high-power blue laser toy readily available over the Internet and increasingly popular among male teens and young adults can cause serious, sometimes irreversible, eye damage, according to a report by investigators from Saudi Arabia’s King Khaled Eye Specialist Hospital and Johns Hopkins Medicine.

14 Nov 2013

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure.

11 Nov 2013

Tissue scarring may help develop new treatments for patients with damaged organs

Patients with damaged organs could be helped by new treatments after scientists have discovered how tissues scar.

10 Nov 2013

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Scientists of the University of Ulm and Columbia University have discovered a diagnostic algorithm to distinguish two subtypes of malignant melanoma. Desmoplastic and spindle cell melanoma may look alike - they often resemble little scars or retractions of the skin - but differ in prognosis and therapeutic options.

4 Nov 2013

Scar News and Research

London hospital implants world’s first leadless pacemaker

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

Cosmetic results after "lumpectomy" differ for African-American versus Caucasian women

Transplanting self-donated Schwann cells aids hind limb functional recovery

Research: Beatboxing may be gentler on injury-prone vocal cords

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Professor wins $1M to create medical devices that lead to greater control of prosthetics in soldiers

Bipolar disorder patients hold contradictory self-associations

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Exposure to high-powered blue handheld laser devices can cause serious eye injuries

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Study sheds new light on neuropsychiatric disorders

Current laser therapy approaches provide effective treatment for excessive scars

Study: Use of bone marrow mononuclear stem cells does not improve heart function

High-power blue laser gadgets can cause serious eye damage

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

Tissue scarring may help develop new treatments for patients with damaged organs

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News